Agape ATP Corp

Aktienanalyse zu Agape ATP Corp (ATPC)

$1.370

+0.131 (+9.59%)Zum Schluss

Loading chart…
Hoch
1.425
Eröffnung
1.320
Volumengewichteter Durchschnittskurs
1.36
Volumen
12.22K
Marktkap.
—
Tief
1.280
Umsatz
16.60K
EV/EBITDA, TTM
0.00

Agape ATP Corporation is a Malaysia-based investment holding company. The principal activity of the Company is to supply health and wellness products, including supplements to assist in cell metabolism, detoxification, blood circulation, anti-aging, and products designed to improve the overall health system of the human body, along with various wellness programs. The Company offers three series of programs, each consisting of different services and products: ATP Zeta Health Program, ENERGETIQUE, and BEAUNIQUE. Its ATP Zeta Health Program is a health program designed to assist in the elimination of various diseases caused by environmental pollutants, unhealthy dietary intake, and unhealthy lifestyles. The ENERGETIQUE series consists of energy mask series, hyaluronic acid, and mousse facial cleanser. Its BEAUNIQUE product series focuses on researching diet’s impact on modifying gene expressions to address genetic variations and deliver a nutrigenomic solution for every individual.

KI-Analyse of Agape ATP Corp (ATPC)

Verkaufen

Agape ATP Corp (ATPC) is not a good buy right now due to its significant price decline and poor financial performance. The current price is $1.25, which is 97.97% lower than its 1-year high of $73.50. The RSI is at 33.51, indicating that the stock is oversold but lacks momentum for recovery. Furthermore, the forward P/E ratio is 0, suggesting no earnings growth expectations, and the gross margin is only 85.96%, which, while high, is overshadowed by the company's overall financial instability. The main risk is the 76.19% year-to-date decline, indicating severe market sentiment against the stock.

Bewertungskennzahlen

Das aktuelle erwartete KGV von Agape ATP Corp (ATPC) beträgt 0.00, verglichen mit dem 5-Jahres-Durchschnitt von 0.00.

Erwartetes KGV

Stark unterbewertet
5J-Durchschnitt P/E
0.00
Aktuelles P/E
0.00
Überbewertet
0.00
Unterbewertet
0.00

Erwartetes EV/EBITDA

Stark unterbewertet
5J-Durchschnitt EV/EBITDA
0.00
Aktuelles EV/EBITDA
0.00
Überbewertet
0.00
Unterbewertet
0.00

Erwartetes KUV

Stark unterbewertet
5J-Durchschnitt P/S
0.00
Aktuelles P/S
0.00
Überbewertet
0.00
Unterbewertet
0.00

Alphio-AI-Kursszenarien für ATPC

Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.

B

Bullisch

Bullisch · 25%ATPC

$1.53

Szenariopreis

B

Basis

Basis · 50%ATPC

$1.40

Szenariopreis

B

Bärisch

Bärisch · 25%ATPC

$1.25

Szenariopreis

Event-Zeitleiste

2026-03-12 (ET)

09:20:00

Agape ATP Regains Nasdaq Listing Compliance

2026-03-10 (ET)

09:30:00

AGAPE ATP Enters Collaboration Agreement with Citadel Investment

2026-02-09 (ET)

20:00:00

Agape ATP Corp Trading Halted, News Pending

2026-02-06 (ET)

13:40:00

Agape ATP Files $200M Mixed Securities Shelf

2026-02-05 (ET)

09:10:00

Agape ATP Corporation Faces Potential Nasdaq Delisting

News

ATPC FAQ – beantwortet von Alphio AI

Agape ATP Corporation is a Malaysia-based investment holding company. The principal activity of the Company is to supply health and wellness products, including supplements to assist in cell metabolism, detoxification, blood circulation, anti-aging, and products designed to improve the overall health system of the human body, along with various wellness programs. The Company offers three series of programs, each consisting of different services and products: ATP Zeta Health Program, ENERGETIQUE, and BEAUNIQUE. Its ATP Zeta Health Program is a health program designed to assist in the elimination of various diseases caused by environmental pollutants, unhealthy dietary intake, and unhealthy lifestyles. The ENERGETIQUE series consists of energy mask series, hyaluronic acid, and mousse facial cleanser. Its BEAUNIQUE product series focuses on researching diet’s impact on modifying gene expressions to address genetic variations and deliver a nutrigenomic solution for every individual. It operates in the Healthcare sector.

Agape ATP Corp (ATPC) is not a good buy right now due to its significant price decline and poor financial performance. The current price is $1.25, which is 97.97% lower than its 1-year high of $73.50. The RSI is at 33.51, indicating that the stock is oversold but lacks momentum for recovery. Furthermore, the forward P/E ratio is 0, suggesting no earnings growth expectations, and the gross margin is only 85.96%, which, while high, is overshadowed by the company's overall financial instability. The main risk is the 76.19% year-to-date decline, indicating severe market sentiment against the stock.

Community

Mehr ↗

Noch keine Beiträge

Registriere dich oder melde dich an, um mitzudiskutieren

Ähnliche Artikel

Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.

Jetzt handeln